145 related articles for article (PubMed ID: 31384986)
1. Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort.
Barrail-Tran A; Goldwirt L; Gelé T; Laforest C; Lavenu A; Danjou H; Radenne S; Leroy V; Houssel-Debry P; Duvoux C; Kamar N; De Ledinghen V; Canva V; Conti F; Durand F; D'Alteroche L; Botta-Fridlund D; Moreno C; Cagnot C; Samuel D; Fougerou-Leurent C; Pageaux GP; Duclos-Vallée JC; Taburet AM; Coilly A
Eur J Clin Pharmacol; 2019 Nov; 75(11):1555-1563. PubMed ID: 31384986
[TBL] [Abstract][Full Text] [Related]
2. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects.
Bifano M; Adamczyk R; Hwang C; Kandoussi H; Marion A; Bertz RJ
Clin Drug Investig; 2015 May; 35(5):281-9. PubMed ID: 25896946
[TBL] [Abstract][Full Text] [Related]
3. Daclatasvir and Sofosbuvir With or Without Ribavirin in Liver Transplant Recipients: A Single-Center Real-World Study.
Mucenic M; Bandeira de Mello Brandao A; Marroni CA; Medeiros Fleck A; Zanotelli ML; Kiss G; Meine MH; Leipnitz I; Soares Schlindwein E; Martini J; Costabeber AM; Sacco FKF; Cracco Cantisani GP
Transplant Proc; 2018 Apr; 50(3):769-771. PubMed ID: 29661434
[TBL] [Abstract][Full Text] [Related]
4. Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.
Coilly A; Fougerou-Leurent C; de Ledinghen V; Houssel-Debry P; Duvoux C; Di Martino V; Radenne S; Kamar N; D'Alteroche L; Leroy V; Canva V; Lebray P; Moreno C; Dumortier J; Silvain C; Besch C; Perre P; Botta-Fridlund D; Anty R; Francoz C; Abergel A; Debette-Gratien M; Conti F; Habersetzer F; Rohel A; Rossignol E; Danjou H; Roque-Afonso AM; Samuel D; Duclos-Vallée JC; Pageaux GP;
J Hepatol; 2016 Oct; 65(4):711-718. PubMed ID: 27262758
[TBL] [Abstract][Full Text] [Related]
5. The impact of directly acting antivirals on the enzymatic liver function of liver transplant recipients with recurrent hepatitis C.
Raschzok N; Schott E; Reutzel-Selke A; Damrah I; Gül-Klein S; Strücker B; Sauer IM; Pratschke J; Eurich D; Stockmann M
Transpl Infect Dis; 2016 Dec; 18(6):896-903. PubMed ID: 27632190
[TBL] [Abstract][Full Text] [Related]
6. Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Harada N; Yoshizumi T; Ikegami T; Itoh S; Furusho N; Kato M; Shimoda S; Fukuhara T; Soejima Y; Maehara Y
Anticancer Res; 2018 Sep; 38(9):5513-5520. PubMed ID: 30194210
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
[TBL] [Abstract][Full Text] [Related]
8. Sofosbuvir-Based Regimens in HIV/HCV Coinfected Patients After Liver Transplantation: Results From the ANRS CO23 CUPILT Study.
Antonini TM; Coilly A; Rossignol E; Fougerou-Leurent C; Dumortier J; Leroy V; Veislinger A; Radenne S; Botta-Fridlund D; Durand F; Houssel-Debry P; Kamar N; Canva V; Perré P; De Ledinghen V; Rohel A; Diallo A; Taburet AM; Samuel D; Pageaux GP; Duclos-Vallée JC;
Transplantation; 2018 Jan; 102(1):119-126. PubMed ID: 28846559
[TBL] [Abstract][Full Text] [Related]
9. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial.
El-Hamamsy M; Montasser IF; Mansy AE; Nabet DE; El-Meteini M
J Clin Pharm Ther; 2019 Jun; 44(3):447-453. PubMed ID: 30714175
[TBL] [Abstract][Full Text] [Related]
10. Recurrent hepatitis C treatment with direct acting antivirals - a real life study at a Brazilian liver transplant center.
Zanaga LP; Santos AG; Ataíde EC; Boin IFSF; Stucchi RSB
Braz J Med Biol Res; 2019; 52(8):e8519. PubMed ID: 31389490
[TBL] [Abstract][Full Text] [Related]
11. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
[TBL] [Abstract][Full Text] [Related]
12. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
13. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons.
Mastrorosa I; Tempestilli M; Notari S; Lorenzini P; Fabbri G; Grilli E; Bellagamba R; Vergori A; Cicalini S; Ammassari A; Agrati C; Antinori A
Eur J Drug Metab Pharmacokinet; 2022 Jan; 47(1):135-142. PubMed ID: 34623616
[TBL] [Abstract][Full Text] [Related]
14. Daclatasvir plasma level and resistance selection in HIV patients with hepatitis C virus cirrhosis treated with daclatasvir, sofosbuvir, and ribavirin.
Parisi SG; Loregian A; Andreis S; Nannetti G; Cavinato S; Basso M; Scaggiante R; Dal Bello F; Messa L; Cattelan AM; Palù G
Int J Infect Dis; 2016 Aug; 49():151-3. PubMed ID: 27378577
[TBL] [Abstract][Full Text] [Related]
15. Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD ≥ 15).
McCaughan GW; Thwaites PA; Roberts SK; Strasser SI; Mitchell J; Morales B; Mason S; Gow P; Wigg A; Tallis C; Jeffrey G; George J; Thompson AJ; Parker FC; Angus PW;
Aliment Pharmacol Ther; 2018 Feb; 47(3):401-411. PubMed ID: 29205432
[TBL] [Abstract][Full Text] [Related]
16. The use of cyclosporine for recurrent hepatitis C after liver transplant: a randomized pilot study.
Firpi RJ; Soldevila-Pico C; Morelli GG; Cabrera R; Levy C; Clark VC; Suman A; Michaels A; Chen C; Nelson DR
Dig Dis Sci; 2010 Jan; 55(1):196-203. PubMed ID: 19798576
[TBL] [Abstract][Full Text] [Related]
17. Predictors of adverse drug reactions associated with ribavirin in direct-acting antiviral therapies for chronic hepatitis C.
Cursino CN; Monteiro PGO; Duarte GDS; Vieira TBQ; Crisante VC; Giordani F; Xavier AR; de Almeida RMVR; Calil-Elias S
Pharmacoepidemiol Drug Saf; 2019 Dec; 28(12):1601-1608. PubMed ID: 31692182
[TBL] [Abstract][Full Text] [Related]
18. A systematic review with meta-analysis: Is ribavirin necessary in sofosbuvir-based direct-acting antiviral therapies for patients with HCV recurrence after liver transplantation?
Xue W; Liu K; Qiu K; Shen Y; Pan Z; Hu P; Peng M; Chen M; Ren H
Int J Infect Dis; 2019 Jun; 83():56-63. PubMed ID: 30959250
[TBL] [Abstract][Full Text] [Related]
19. Virological Response to Sofosbuvir-Based Treatment in Renal Transplant Recipients With Hepatitis C in Pakistan.
Hanif FM; Mandhwani R; Lail G; Luck NH; Aziz T
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):198-201. PubMed ID: 30777554
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
Goel A; Bhargava R; Rai P; Aggarwal R
Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
